e-Therapeutics at a Glance

e-Therapeutics is pioneering the new science of network pharmacology in drug discovery. Scientists at the Company's Network Pharmacology Centre near Oxford are seeking novel treatments for cancer and degenerative diseases of the nervous system. The company has advanced two drugs into clinical trial - one for cancer and one for major depressive disorder. e-Therapeutics has a site in Newcastle-upon-Tyne in addition to its new centre near Oxford. The Company is listed on the AIM market of the London Stock Exchange (ticker ETX).


Listing and Share Price

e-Therapeutics is listed on the AIM market of the London Stock Exchange under the ticker symbol ETX.


Press Releases

For latest news click here and for a full list of all announcements, click here.


Events

Proactive Investors Event, Manchester, UK, 26 June 2013
BIA UK CEO & Investor Forum, Hertfordshire, UK, July 11 2013
BioEurope, Vienna, Austria, 4-6 November

 

 

Presentations and Reports

Access our latest corporate presentation and financial reports.


Major Shareholders*

  • Invesco - 131,331,539 (49.8%)
  • Aviva - 42,750,000 (16.2%)

  • Malcolm Young - 20,644,958 (7.8%)
  • Henderson Global Investors - 17,539,408 (6.7%)
  • Octopus Group – 11,097,658 (4.2%)
The total number of ordinary shares as of 18 March 2013 (most recent issue of new shares) was 263,579,338.


Analyst Coverage

The following analysts cover e-Therapeutics:

  • Savvas Neophytou, Panmure Gordon
  • Franc Gregori, Edison*

  • Emanuil Halicioglu, Growth Equities & Company Research*

*Designates that research is ‘paid-for’ coverage produced under a contract with e-Therapeutics


Advisers

The following link has details of the Company’s Nominated Adviser and other key advisers: Advisers


Contacts

For investor relations enquiries and holdings notifications:

Daniel Elger, CFO


Registrar:


For questions concerning share certificates or changes of shareholder address or other details, please contact Neville Registars:
Neville Registrars Limited
Neville House,
18 Laurel Lane
Halesowen
West Midlands
B63 3DA

Tel: +44 (0) 121 585 1131
Fax: +44 (0) 121 585 1132



Investor Relations and governance pages last updated 03 June 2013
 
Array